Henni-Karoliina Ropponen

Henni-Karoliina Ropponen is a Venture Analyst at AMR Action Fund, responsible for deal sourcing, due diligence, and deal execution in antimicrobial and antifungal companies. Henni-Karoliina also serves as a Board Observer for portfolio companies Elion Therapeutics and UTILITY therapeutics, focusing on innovative treatments for fungal infections and FDA-approved assets, respectively. Previous experience includes a role as a Scientific Officer at the Global Antibiotic R&D Partnership, where responsibilities encompassed antibiotic discovery and research data management. Henni-Karoliina's early career involved positions at Roche and the Helmholtz-Institute for Pharmaceutical Research Saarland, with a PhD in Medicinal Chemistry and extensive experience in research and development of antibiotics. Educational credentials include a Doctor of Natural Sciences from Universität des Saarlandes and a Master's in Chemistry with Drug Discovery from the University of Strathclyde.